In brief
The Democratic Republic of Congo’s 2026 Ebola outbreak is already putting its death toll past the 2014‑16 wave, according to WHO Director‑General Tedros. With 4,300 confirmed cases and more than 2,000 deaths, the WHO aims to curb the spread within three months, though full eradication remains out of reach. The Bundibugyo strain is rare and has no approved vaccine, but clinical trials are underway using Oxford‑AstraZeneca technology. Doctors say the virus began spreading in February, often mistaking symptoms for malaria or typhoid—a major hurdle in the region’s unstable eastern provinces. The outbreak highlights the urgent need for new treatments and global preparedness.
The Democratic Republic of Congo’s latest Ebola outbreak is already putting its death toll past the 2014‑16 wave, according to WHO Director‑General Tedros Adhanom Ghebreyesus. He warned that, at the current pace, the 2026 outbreak would eclipse the previous record of at least 11,000 deaths.
Since being declared on 15 May, the epidemic has registered over 4,300 cases and more than 2,000 deaths. The WHO hopes to reverse the spread within three months, but points out this goal means bringing transmission under control—not ending the outbreak entirely.
Health officials say the virus began spreading in February, before the official declaration, and that early cases were often misdiagnosed as malaria or typhoid. WHO Africa director Dr. Mohamed Janabi described the situation as the virus being “ahead of us.”
The 2026 outbreak is caused by the Bundibugyo species of Ebola, which has previously caused only two known outbreaks in 2007 and 2012. No approved vaccine or therapeutic drugs can treat this particular strain, though a University of Oxford trial is underway using technology similar to the AstraZeneca COVID vaccine.
Other groups are also developing vaccines and an ongoing WHO-sponsored study in the DRC is testing whether existing antiviral therapies can improve survival rates. As the outbreak continues amid regional instability, health workers reach only about 30% of cases, complicating containment.
